NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. Annual Report - How They Did This Year

Thinking about investing in NRX Pharmaceuticals, Inc.? This guide explains their past year in simple terms. We'll cover the important details. This will help you understand the company. Then you can decide if it fits your investment goals.

We'll discuss what they do and their financial health. We'll also look at their major successes and challenges. Finally, we'll explore their future plans. We'll base this summary on their official reports. This means you'll only see verified information.

1. What does this company do and how did they perform this year? NRX Pharmaceuticals is a drug development company. They focus on new treatments for brain and nervous system disorders. These include suicidal depression, chronic pain, PTSD, and schizophrenia. This past year (through 2025), NRX Pharmaceuticals advanced its drug candidates. They formed new partnerships. In 2024, they signed a licensing deal with Alvogen. In 2025, they also secured a licensing deal with Sarah Herzog Memorial Hospital. This deal includes a milestone for finishing early-stage human trials. This shows they are actively bringing new therapies to market. They are moving their research through human trials (Phase I, II, and III). They want to sell these drugs in the US and Europe. A big change in 2025 was buying Dura Medical on September 8, 2025. This expanded NRX Pharmaceuticals' business. It now includes medical equipment and services, not just drug development. This is a big strategic move that broadens what the company does. NRX Pharmaceuticals also founded and owns most of HOPE Therapeutics, Inc. This company provides specialized mental health care services. HOPE Therapeutics started in February 2024. It aims to provide advanced psychiatric treatments. These include ketamine, Spravato, and their own NRX-101. Other therapies like Transcranial Magnetic Stimulation (TMS) are also offered. HOPE Therapeutics generated its first money from patient care in Q4 2025. It now operates in five Florida locations. They plan to expand to eight or more by mid-2026. Their main drugs in development, all targeting a specific brain pathway, are:

   • KETAFREE™: This is a generic version of ketamine without preservatives. They asked the FDA for approval in September 2025. They received early positive feedback. This included a preliminary determination of "no deficiency" compared to the original drug. They plan to start selling this in Q3 2026. The market for generic ketamine is over $750 million each year. They finished making it and confirmed it stays good for three years.
   • NRX-100: This is a preservative-free ketamine for IV (into a vein) infusion. The FDA gave it "Fast Track status" for all types of depression and related disorders. This is much broader than its original designation for just bipolar depression. This means NRX-100's potential market has grown significantly. It could now help an estimated 13 million Americans. The FDA also noted that NRX-100 addresses a "medical need not yet met." This is important for special programs. They are using "real-world patient data" to help get it approved. The FDA agreed to review this. They plan to ask for full FDA approval in Q2 2026. A similar nasal drug sells about $2 billion each year. They also finished making it and confirmed a three-year shelf life. The company seeks faster approval for NRX-100. Licensed data shows IV ketamine reduces suicidal thoughts and depression. It works better than a dummy treatment or other drugs. Effects start within hours and last about a week. A study funded by PCORI, a patient research group, also showed ketamine was as effective as ECT (shock therapy) for depression over six months. But it was much safer. No ketamine patients reported memory loss, compared to 30% for ECT patients. The company believes this data, plus other trials, might allow early FDA market access. But they must provide more confirming data within five years. They also use real-world patient data from about 70,000 patients. This supports the good results from controlled trials. This real-world data also suggests IV ketamine (like NRX-100) looks better than nasal SPRAVATO®. This is a big competitive edge.
   • NRX-101: This is an oral combination drug for bipolar depression with suicidal thoughts. This drug has "Breakthrough Therapy status" from the FDA. This means it gets a faster review. They began the approval process, seeking faster approval. They submitted manufacturing data for its new drug application (NDA). Recent findings suggest its key ingredient, D-cycloserine, could greatly improve another mental health treatment, TMS. In 2025, management focused on preparing the NDA for NRX-101. They submitted over 80,000 pages of data in July 2025. This included manufacturing, non-clinical, and patient trial information. This drug showed a clear benefit in reducing suicidal thoughts and akathisia. Akathisia is a feeling of inner restlessness. This was seen in two well-controlled trials, compared to lurasidone. NRX Pharmaceuticals believes NRX-101 is the only pill proven in two trials to reduce active suicidal thoughts and akathisia. They plan to seek faster approval for a specific patient group. These are people with "Suicidal Bipolar Depression in patients with Akathisia and Active Suicidal Ideation despite standard of care therapy."

2. Financial performance - sales, profit, growth NRX Pharmaceuticals is a drug development company. Its drugs are not yet selling much. But in 2025, the company made money from different sources. These include payments from commercial insurance, Medicare, and patients paying directly. This shows they have some sales activity or are getting ready for it. The money from commercial insurance, Medicare, and direct patient payments likely comes from the Dura Medical business they bought. This business focuses on medical equipment and services. This adds a new way for the company to make money. Importantly, their HOPE Therapeutics subsidiary also made its first money from patient care in Q4 2025. This is a good step toward making more money. The company had costs for general operations and research in both 2024 and 2025. This is normal for such a company. For a drug development company, research costs are usually high. They often spend more on research than general operations. This is because they invest heavily in human trials and getting approvals. The company is getting ready for big future sales. Their generic ketamine drug (KETAFREE™) is aiming for a market over $750 million each year. Their NRX-100 drug targets a market worth about $2 billion each year. These are potential market sizes. They show big sales opportunities if their drugs succeed.

3. Major successes and challenges this year Successes: A big positive this year was signing new licensing deals. These include Alvogen in 2024 and Sarah Herzog Memorial Hospital in 2025. These deals are key to developing and selling their treatments. They could bring future growth and sales. Another major success was buying Dura Medical in September 2025. This made their HOPE Therapeutics subsidiary a clinical business that earns money in Q4 2025. They also bought a stake in Cohen and Associates in October 2025. These moves broaden their business. This creates new ways to make money beyond drug development. The company made big steps forward with its drugs in development:

   • KETAFREE™: They asked the FDA for approval and got good feedback. Sales could start in Q3 2026. They also finished making it and showed it stays good for three years.
   • NRX-100: The FDA gave it expanded "Fast Track status" for all types of depression. This could grow its market tenfold to 13 million Americans. It also qualifies for a special FDA program. They plan to ask for full FDA approval in Q2 2026. The FDA agreed to review their real-world patient data. Manufacturing is also complete and it stays good for three years. They even got an FDA fee waiver, saving a lot of money. Further successes for NRX-100 include strong patient trial data showing it works. Licensed data indicates IV ketamine is better than a dummy treatment for reducing suicidal thoughts and depression. A PCORI-funded trial showed it was as good as ECT for depression, but much safer (no memory loss). Their real-world patient data also looks good compared to nasal SPRAVATO®. They plan a 450-person trial. It will compare NRX-100 directly to nasal S-ketamine. They expect it to be at least as good. It may be better for suicidal thoughts.
   • NRX-101: It received "Breakthrough Therapy status." They began the FDA approval process, seeking faster approval. They submitted manufacturing data for its new drug application. New findings suggest its key ingredient could greatly improve other mental health treatments like TMS. A major success for NRX-101 was submitting over 80,000 pages of data for its new drug application in July 2025. This drug also showed a clear benefit in reducing suicidal thoughts and akathisia. This was seen in two well-controlled trials. This makes it a unique pill for a specific group of patients with high needs.
   • HOPE Therapeutics also reached a big goal by starting the ONE-D protocol. This is a one-day TMS treatment with D-cycloserine. It has shown good response and recovery rates for severe depression. They are among the first nationwide to offer this. They also made important new leaders, including Professor Joshua Brown as Chief Medical Innovation Officer. They formed key partnerships with companies like neurocare AG and EMOBOT, Inc. Challenges:
   • A big challenge for current investors was the large increase in shares. This caused significant dilution. The total common shares more than doubled. They jumped from about 14.6 million in late 2024 to about 31.7 million by late 2025. By March 23, 2026, it was 33,067,630 shares. This dilution came from raising money. They used "At-The-Market" (ATM) offerings, private sales, registered offerings, and gave stock to vendors. Converting debt (like Anson and Streeterville notes) and preferred stock into common shares also added to this increase. Each existing share now owns a smaller piece of the company. This can lower value for current investors and push down the stock price.
   • Another important event in 2024 was a reverse stock split. This means the company reduced its total shares. The price per share went up proportionally. It doesn't immediately change your total investment value. Companies often do this to raise their stock price. This helps them meet exchange rules or attract big investors. But it can signal stock struggles. Investors might see it negatively, hurting confidence.

4. Financial health - cash, debt, liquidity NRX Pharmaceuticals actively raised money over the past year. They used different ways. This included selling new shares through "At-The-Market" (ATM) offerings, private sales, and registered offerings. They also gave stock to vendors. They also turned different types of debt, like convertible notes (from Streeterville and Anson), and Series A Preferred Stock into common shares. As part of these fundraising efforts, the company also issued warrants. These give holders the right to buy stock later at a set price. These actions helped them get money and handle debt. But they greatly increased available shares. This caused dilution for current investors. This strategy helps with immediate cash needs and debt reduction. But current investors now own a smaller piece of the company. This fundraising trend continued even after the fiscal year ended. For example, the company did another "At-The-Market" (ATM) offering between February and March 2026. This is a way to sell new shares directly to the market for more cash. This shows they still need money and keep relying on selling new shares. On a positive note, the company expects to get money that won't dilute shares. This means they won't issue more shares, protecting current investors. This funding will come from a government agency. It will support the Phase 2b/3 trial for NRX-101. This is good for their financial plans. Their HOPE Therapeutics subsidiary also got money from the B-Group. This helped them buy its first clinics. The market value of common stock not owned by insiders was $57.4 million as of June 30, 2025. This shows the company's public shares and total market value then.

5. Key risks that could hurt the stock price

   • Share Dilution: The significant dilution of common stock is a main risk. The company frequently uses different ways to raise money. This includes ATM offerings, private sales, registered offerings, stock given to vendors, and turning debt and preferred stock into common shares. This has more than doubled the total shares. It reached 33,067,630 shares by March 23, 2026. They also issued warrants. These could lead to even more shares if exercised. This "overhang" can push down the stock price. More shares continuously hurt each share's value. This makes it harder for the stock price to rise, even with good news. The company continued with an ATM offering in early 2026. This was after the 2025 fiscal year ended. This shows dilution is an ongoing way to raise money. It could keep pressuring the stock price.
   • Reverse Stock Split: The reverse stock split in 2024 might help the company meet listing rules. But investors can see it as a sign of stock struggles. This could hurt investor confidence. It doesn't change the company's core value. But it can make it seem weaker.
   • Cybersecurity Risks: NRX faces cybersecurity risks, like any company. This is especially true in the sensitive drug sector, handling patient data and patents. Their Audit Committee (board members) checks these risks yearly. They work with management and experts to prevent threats. But cyber incidents (like data breaches or system outages) are always a risk. They could harm operations, data security, rules compliance, and reputation.
   • Convertible Debt: Turning debt into ownership can lower immediate debt. But the terms of these convertible notes and their conversion can create uncertainty. More shares are issued for these conversions, adding to dilution.
   • General Biotech Risks: As a drug development company, NRX faces inherent risks. These include a short operating history. This means no long track record of sales or profit. They may also have trouble hiring and keeping employees. Especially skilled scientists and medical staff. There is strong competition from bigger, older drug companies. Regulatory challenges exist. FDA approvals are complex, long, and uncertain. Manufacturing problems can arise, including ensuring consistent quality and supply. They also need to protect their patents. These can be challenged or expire. No guarantee their drugs in development will get FDA approval or sell well. This is true even with good trial data. For example, they believe existing data for NRX-100 might allow early market access. But the FDA still requires confirming data within five years for faster approval. This is an ongoing challenge. It's a condition to keep approval.

6. Competitive position NRX Pharmaceuticals is placing its drugs in development in competitive markets:

   • KETAFREE™: As generic ketamine without preservatives, it wants to gain part of the existing $750 million+ generic ketamine market. Their petition to remove a toxic preservative from other ketamine products could give them an edge. They offer a safer option. This may attract more patients and doctors.
   • NRX-100: This IV ketamine aims to compete with existing treatments. These include nasal S-ketamine (SPRAVATO®), which sells about $2 billion each year. Its expanded "Fast Track status" for all types of depression and the FDA's "unmet medical need" finding give it a strong edge. This could mean faster review and wider market access. Early data suggests NRX-100 may work faster and stronger. This could be a big plus for treating severe depression and suicidal thoughts. NRX-100's competitive edge grows. Licensed patient data shows it's better than a dummy treatment for suicidal thoughts and depression. A PCORI study showed it's as good as ECT for depression, but much safer (no memory loss). Their real-world patient data also looks good compared to nasal SPRAVATO®. This suggests it could be a strong competitor. It may offer a more effective or safer choice. They plan a 450-person trial. It will compare NRX-100 directly to nasal S-ketamine. They expect it to be at least as good. It may be better for suicidal thoughts. This would strengthen its competitive position.
   • NRX-101: It has "Breakthrough Therapy status." They seek faster approval for a specific patient group. These are people with bipolar depression and suicidal thoughts. It targets a medical need not yet met. It could greatly improve TMS effects. This creates a unique competitive angle. This is especially true with their partnership with neurocare AG, allowing for combined treatments. NRX-101 stands out. The company believes it's the only pill shown in two trials to reduce active suicidal thoughts and akathisia. This gives it a unique spot for this specific, high-need patient group. Current treatments may not be enough or have bad side effects. Buying Dura Medical and growing HOPE Therapeutics also broadens their competitive landscape. This moves them into medical equipment, services, and direct patient care. This is alongside their drug development. HOPE focuses on advanced psychiatry. They are among the first to offer the high-response ONE-D protocol for TMS. This gives them a unique spot in mental health treatment. They also explore military TMS technology and PTSD treatments for first responders. This taps into specialized, underserved markets.

7. Leadership or strategy changes The Audit Committee (board members) actively oversees cybersecurity risks. This shows a structured way to manage a key business and money risk. A big change in strategy this year was buying Dura Medical and quickly growing HOPE Therapeutics. This greatly broadens NRX Pharmaceuticals' business. It adds medical equipment, services, and direct patient care to their main drug development business. This shows a clear plan to diversify and grow beyond just drug development. They aim for many ways to make money. HOPE Therapeutics also made important new leaders. These include Professor Joshua Brown, MD, PhD, as Chief Medical Innovation Officer. Dr. Rebecca Cohen became Medical Director. This brings in top talent to lead their clinical plans and innovation. Their focus on advanced TMS techniques (like neuro-navigation and ONE-D protocol) and partnerships (with neurocare AG and EMOBOT, Inc.) shows a forward-thinking approach to mental health care. The company's strategy is clear. They want to quickly move their drugs through FDA pathways. These include ANDA for generics, NDA for new drugs, Fast Track, Breakthrough Therapy, and Real World Evidence. Their goal is to achieve sales. They focus on preservative-free drugs and use new FDA guidance (like for real-world patient data). This shows a strategic way to develop drugs and enter the market. They aim for unique products and faster approval. They put great effort into preparing and submitting over 80,000 pages for the NRX-101 NDA in July 2025. This also shows a strategic focus. They want to push their key drugs through approval as fast as possible.

8. Future outlook The licensing deal with Sarah Herzog Memorial Hospital shows a clear path for drug development. It includes goals for finishing early, mid, and late-stage human trials. Beyond trials, the deal also sets goals. These include the first commercial sale of the licensed drug in the US and Europe. It also sets an annual sales target. This shows a strong focus on moving their drugs through all tests. They want to bring new therapies to global markets. Their goal is big future sales. Looking into early 2026, the company kept raising money through an "At-The-Market" (ATM) offering. This suggests that getting money for daily operations and future growth remains a key company focus. On a positive note, they expect money from a government agency. This funding won't dilute shares. It will support the NRX-101 Phase 2b/3 trial. This trial is expected to start in Q2 2026. This non-dilutive money is vital. It lets the company advance a key drug without further diluting current investors. Their HOPE Therapeutics subsidiary plans to grow to eight or more locations by late Q2 2026. It also seeks to buy an innovative PTSD treatment program for first responders. This shows aggressive growth plans for its service business. NRX Pharmaceuticals has several important goals coming up:

   • Q3 2026: They plan to start selling KETAFREE™. This would be their first potential drug sales.
   • Q2 2026: They expect to file the New Drug Application (NDA) for NRX-100. They also plan a 450-person trial. It will compare NRX-100 to nasal S-ketamine. They expect it to be at least as effective. It may be better for suicidal thoughts. This could greatly impact how well it sells.
   • Q2 2026: The Phase 2b/3 trial for NRX-101 is expected to start. It has non-dilutive government funding. This is a critical step toward its potential approval.
   • They continue to seek faster approval for NRX-101. This is for its specific use: suicidal bipolar depression with akathisia and active suicidal thoughts. They also explore its potential to improve TMS treatments.
   • They keep focusing on human trials and selling their licensed drugs. This is for both the US and Europe. It shows a global market strategy.
   • HOPE Therapeutics will keep growing its clinical presence. It will also develop advanced TMS therapies. This includes military-focused technology. Their goal is to capture more of the mental health services market.

9. Market trends or regulatory changes affecting them A big regulatory change NRX is using is the FDA's new guidance in Q3 2025. It lets companies submit "real-world patient data" to show a drug's effectiveness. This is important. It can speed up approvals. It may cut time and cost for traditional trials, as seen with NRX-100. The FDA expanded NRX-100's "Fast Track status" to cover all types of depression. The FDA also found an "unmet medical need". These are big regulatory advantages. They could qualify it for special programs. These include the Commissioner’s National Priority Voucher Program. This can offer valuable benefits or faster review. The FDA's work with NRX, including a meeting and fee waiver, shows a positive regulatory environment. It suggests the agency sees potential in their drugs. The company has also submitted a citizen petition to the FDA. They want to remove benzethonium chloride, a toxic preservative, from all commercial ketamine products. If successful, this could help their preservative-free KETAFREE™. Other generic ketamine products might become less appealing. They might even need reformulation.